Last reviewed 2026-04-20 · How we verify

ZIPRASIDONE MESYLATE

Ziprasidone's mechanism involves blocking dopamine D2 and serotonin 5HT2 receptors.

At a glance

Mechanism of action

Ziprasidone works by blocking specific receptors in the brain. It targets dopamine D2 and serotonin 5HT2 receptors, which helps in treating the listed conditions by modulating neurotransmitter activity.

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone mesylate for injection is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone mesylate for injection is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )

Common side effects

No common side effects on file.

Drug interactions

• Drugs that prolong the QT interval
• Centrally acting drugs
• Antihypertensive agents
• Levodopa and dopamine agonists
• Serotonergic drugs (e.g., SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, St. John’s Wort)
• Carbamazepine
• Ketoconazole
• Cimetidine
• Antacid (Maalox®)

Key clinical trials

• An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
• Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes (PHASE3)
• Maternal And Infant Antipsychotic Study
• A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
• Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia (PHASE1)
• Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) (PHASE4)
• Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
• Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.